浙江省人民医院
Zhejiang Provincial People's Hospital
在本站收录的 61 种疾病中,这家医院列在其中 27 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
浙江省人民医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma4 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma119 篇牵头论文
- 胃癌Stomach cancer38 篇牵头论文
- 肺癌Lung cancer69 篇牵头论文牵头 1 项开放试验
- 胰腺癌Pancreatic cancer53 篇牵头论文牵头 3 项开放试验
- 乳腺癌Breast cancer74 篇牵头论文牵头 1 项开放试验
- 胶质瘤Glioma24 篇牵头论文牵头 1 项开放试验
- 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
- 骨肉瘤Osteosarcoma4 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 尤文肉瘤Ewing sarcoma0 篇牵头论文
- 多发性骨髓瘤Multiple myeloma10 篇牵头论文
- 淋巴瘤Lymphoma15 篇牵头论文牵头 1 项开放试验
- 重症肌无力Myasthenia gravis2 篇牵头论文
- 冠心病Coronary heart disease12 篇牵头论文
- 先天性心脏病Congenital heart disease5 篇牵头论文
- 脊柱侧弯Scoliosis3 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- 法布雷病Fabry disease1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
- 白塞病Behçet disease0 篇牵头论文
- IgA 肾病IgA nephropathy4 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis4 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文
未列出的收录疾病:肝母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 8 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- 分期
- 不分期
- 开始
- 2023-06
- 发布
- 登记号
- NCT05892354
年龄 18 岁 至 70 岁(登记的条件)
牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Hypomethylation-associated ELF3 helps nasopharyngeal carcinoma to escape immune surveillance via MUC16-mediated glycolytic metabolic reprogramming.
- E2F1-EP300 co-activator complex potentiates immune escape in nasopharyngeal carcinoma through the mediation of MELK.
- E2F3 renders an immunosuppressive tumor microenvironment in nasopharyngeal carcinoma: Involvements of the transcription activation of PRC1 and BIRC5.
- The anticancer effect of EGFR-targeting artificial microRNA controlled by SLPI promoter in nasopharyngeal carcinoma.
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文4
- Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
- Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.
- Annexin A2 combined with TTK accelerates esophageal cancer progression via the Akt/mTOR signaling pathway.
- Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review).
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
PubMed 以外找到的论文(未计入)12
- Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
- Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.
- Effect of PLCE1-driven aerobic glycolysis through ENO1 modulation on immune evasion in esophageal squamous cell carcinoma (ESCC).
- 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
- 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
- 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
- Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).
- P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
- Epigenetically inhibiting CYP3A5 modulates the migration and invasion of esophageal squamous cell carcinoma via ZEB2
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 119 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
牵头的论文119
- Development and validation of machine learning-based model for predicting early recurrence for patients with HBV-associated hepatocellular carcinoma after curative hepatectomy.
- Hepatic stellate cells shape the ECM-disorganized and immunosuppressive microenvironment via CCL11/CCR3 axis in lenvatinib-treated hepatocellular carcinoma.
- Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.
- A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma.
- Tumor-Targeted PLGA Nanospheres Enhance Therapeutic Effect of Lenvatinib in Hepatocellular Carcinoma via Photothermal and Photodynamic Therapy.
- Cancer Cell-Derived Exosomal miR-500a-3p Modulates Hepatic Stellate Cell Activation and the Immunosuppressive Microenvironment.
- Transcription factor FOXC2 regulates miR-145/ADAMTS5 axis to inhibit angiogenesis in hepatocellular carcinoma via circular RNA 0002898.
- Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia.
- Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC.
- Developing a novel predictive model for identifying risk factors associated with being lost to follow-up among high-risk patients for recurrence following radical resection of hepatocellular carcinoma: the first report.
- Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review.
- Noninvasive prediction of Glypican-3 expression in hepatocellular carcinoma using Habitat-based and peritumoral CT radiomics: a nomogram approach.
- RSK2-mediated phosphorylation and degradation of UBE2O inhibits hepatocellular carcinoma growth and resistance to radiotherapy.
- YY1 induced USP13 transcriptional activation drives the malignant progression of hepatocellular carcinoma by deubiquitinating WWP1.
- IGF2BP1/AIFM2 axis regulates ferroptosis and glycolysis to drive hepatocellular carcinoma progression.
- Targeting Glycolytic Enzymes with 3-Bromopyruvic Acid to Enhance the Efficacy of Interventional Embolization in Hepatocellular Carcinoma.
- Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator.
- Outcomes and risk factors for liver transplantation using steatotic grafts for hepatocellular carcinoma: a multicenter study.
- Dual-Mode Treatment of Hepatocellular Carcinoma Using RGD Cyclopeptide-Modified Liposomes Loaded with Ce6/DOX.
- Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling.
- Tumor-microenvironment responsive nanomodulator for near infrared photothermal immunotherapy of hepatocellular carcinoma.
- Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria.
- Perioperative and long-term outcomes of laparoscopic liver resection for combined hepatocellular carcinoma and cholangiocarcinoma versus intrahepatic cholangiocarcinoma: A propensity score matching analysis.
- The value of prealbumin in predicting post hepatectomy liver failure for patients with hepatocellular carcinoma undergoing major hepatectomy.
- Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma.
- Radiomics analysis based on dynamic contrast-enhanced MRI for predicting early recurrence after hepatectomy in hepatocellular carcinoma patients.
- Unraveling the Causal Links Between Immune Traits and Hepatocellular Carcinoma: Insights From a Bi-Directional Mendelian Randomization Study.
- Prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma through ultrasound elastography.
- Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis.
- Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis.
- Development and validation of prealbumin-bilirubin score (preALBI score) for predicting long-term survival after hepatectomy for hepatocellular carcinoma: A multicenter analysis versus ALBI score.
- The Prognostic Value of Preoperative Serum Markers and Risk Classification in Patients with Hepatocellular Carcinoma.
- Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy.
- Establishment of a novel ferroptosis-correlative lncRNA signature and validation of ST3GAL4-AS1 for predicting overall survival of hepatocellular carcinoma.
- Survival benefit of adjuvant TACE for patients with hepatocellular carcinoma and child-pugh B7 or B8 after hepatectomy.
- Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis.
- Comparison of percutaneous microwave/radiofrequency ablation liver partition and portal vein embolization versus transarterial chemoembolization and portal vein embolization for planned hepatectomy with insufficient future liver remnant.
- Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.
- FAM188B promotes the growth, metastasis, and invasion of hepatocellular carcinoma by targeting the hnRNPA1/PKM2 axis.
- UCHL3 promotes hepatocellular carcinoma progression by stabilizing EEF1A1 through deubiquitination.
- OTUD5 promotes the growth of hepatocellular carcinoma by deubiquitinating and stabilizing SLC38A1.
- USP40 promotes hepatocellular carcinoma cell proliferation, migration and stemness by deubiquitinating and stabilizing Claudin1.
- Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.
- Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma.
- Multicenter propensity score-matched analysis to compare perioperative morbidity after laparoscopic or robotic complex hepatectomy for solitary hepatocellular carcinoma.
- Mild photothermal activation of TRPV1 pathway for enhanced calcium ion overload therapy of hepatocellular carcinoma.
- Unveiling the Role of Mechanical Microenvironment in Hepatocellular Carcinoma: Molecular Mechanisms and Implications for Therapeutic Strategies.
- Black Phosphorus Nanosheets-Loaded Single-Atom Gold Nanoenzymes for Enhanced Photodynamic Therapy of Hepatocellular Carcinoma.
- Letter to Editor: 'Identification of patients with favorable prognosis after resection in intermediate-stage hepatocellular carcinoma'.
- Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.
- LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF-1α-Dependent Glucose Metabolic Reprogramming.
- Letter to the editor: 'A simple scoring system to predict early recurrence after surgical resection for hepatocellular carcinoma'.
- Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.
- Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis.
- The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma.
- Letter to the editor: "Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results".
- Comprehensive analysis of cell death genes in hepatocellular carcinoma based on multi-omics data.
- Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study.
- Pure laparoscopic resection of a large caudate-lobe mass guided by three-dimensional reconstruction and green fluorescence navigation.
- Prognostic value of platelet distribution width to lymphocyte ratio in patients with hepatocellular carcinoma following hepatectomy.
- MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.
- UBE2K promotes the malignant progression of hepatocellular carcinoma by regulating c-Myc.
- Polydopamine-Modified Zeolite Imidazole Framework Drug Delivery System for Photothermal Chemotherapy of Hepatocellular Carcinoma.
- Upregulation of MED7 was associated with progression in hepatocellular carcinoma.
- The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis.
- Exosomal miR-374c-5p derived from mesenchymal stem cells suppresses epithelial-mesenchymal transition of hepatocellular carcinoma via the LIMK1-Wnt/β-catenin axis.
- Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.
- Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma.
- Transcatheter arterial chemoembolization after percutaneous microwave ablation and portal vein embolization for advanced hepatocellular carcinoma.
- Association of severity in the grading of microvascular invasion with long-term oncological prognosis after liver resection for early-stage hepatocellular carcinoma: a multicenter retrospective cohort study from a hepatitis B virus-endemic
- Five machine learning-based radiomics models for preoperative prediction of histological grade in hepatocellular carcinoma.
- Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinoma.
- Hypoxia-induced UBE2K promotes the malignant progression of HCC.
- LncRNA FRMD6-AS1 promotes hepatocellular carcinoma cell migration and stemness by regulating SENP1/HIF-1α axis.
- A novel metabolism-related gene signature in patients with hepatocellular carcinoma.
- Short- and long-term outcomes of laparoscopic versus open liver resection for large hepatocellular carcinoma: a propensity score study.
- Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics.
- Editorial: non-viral hepatocellular carcinoma surveillance-an increasingly severe public health issue.
- Letter: sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.
- Diagnostic accuracy of circulating microRNAs for hepatitis C virus-associated hepatocellular carcinoma: a systematic review and meta-analysis.
- Actinidia chinensis Planch Root extract suppresses the growth and metastasis of hypopharyngeal carcinoma by inhibiting E2F Transcription Factor 1-mediated MNX1 antisense RNA 1.
- Graphene quantum dots mediated magnetic chitosan drug delivery nanosystems for targeting synergistic photothermal-chemotherapy of hepatocellular carcinoma.
- High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma.
- Resistance of Lenvatinib in Hepatocellular Carcinoma.
- Letter to editor: Does age effect on the short- and long-term outcomes of patients undergoing liver resection for hepatocellular carcinoma?
- Impact of diabetes mellitus on the long-term prognosis of patients with hepatocellular carcinoma after hepatectomy.
- Low expression of moonlight gene ALAD is correlated with poor prognosis in hepatocellular carcinoma.
- Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty live
- LncRNA ALKBH3-AS1 enhances ALKBH3 mRNA stability to promote hepatocellular carcinoma cell proliferation and invasion.
- Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.
- HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?
- Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
- Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?
- The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.
- The updated BCLC staging system needs further refinement: A surgeon's perspective.
- The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma.
- PHF21A expression as a biomarker of hepatocellular carcinoma progression and prognosis.
- Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress.
- Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma.
- Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.
- An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model.
- Long-term oncologic outcomes of liver resection for hepatocellular carcinoma in adolescents and young adults: A multicenter study from a hepatitis B virus-endemic area.
- Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma.
- Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis.
- HIF-1α-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression.
- An Autophagy-Related Gene-Based Prognostic Risk Signature for Hepatocellular Carcinoma: Construction and Validation.
- Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study.
- Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study.
- UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
- Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.
- Comment on: Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma.
- ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis.
- Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.
- High expression of YKT6 associated with progression and poor prognosis of hepatocellular carcinoma.
- Biointerfacing Antagonizing T-Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy.
- Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management.
- The Clinical Significance of RMI2 in Hepatocellular Carcinoma.
- Low Expression of KAT6B May Affect Prognosis in Hepatocellular Carcinoma.
- Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 38 篇,占 0.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 9 家医院列在胃癌下全国有 211 家医院列在胃癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Phase 2 Clinical Study of ABSK061 and ABSK043
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06632262
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文38
- Prediction model based on gut microbiota as a non-invasive tool for gastric cancer diagnosis.
- ASPN was higher expression in gastric cancer and associated with poor prognosis through promoting invasion and migration and inducing macrophage M2 polarization.
- Histone lactylation drives METTL3 upregulation-mediated RNA m6A modification of CCT2 to hinder CD8+ T cell survival in gastric cancer.
- Integrated analysis of single-cell and bulk transcriptomes reveals the prognostic value of polyamine metabolism biomarkers and immune microenvironment features in gastric cancer.
- NRAV promoted the malignant progression of gastric cancer.
- FGL1 facilitates rather than suppresses anticancer immunity against microsatellite instable gastric cancer.
- PICK1 modulates the proliferation and migration of gastric cancer cells by regulating TLR4.
- The Causal Role of Gut Microbiota and Immune Cell Mediation in Gastroenteropancreatic Neuroendocrine Neoplasms: A Mendelian Randomization Study.
- Explore the role of CBS in stomach adenocarcinoma based on the sulfur-containing amino acid metabolism network.
- 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer.
- M6A methylation of FKFB3 reduced pyroptosis of gastric cancer by NLRP3.
- RARB associated with MSI, affects progression and prognosis of gastric cancer.
- A prognostic risk model based on lactate metabolism and transport-related lncRNAs for gastric adenocarcinoma.
- WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα.
- WYC-209 suppresses gastric cancer by down-regulating FGF18 via inactivating the STAT3 signaling pathway.
- F2RL3 Regulates Epithelial-Mesenchymal Transition and Angiogenesis in Gastric Cancer through the Rap1/MAPK Signaling Pathway.
- Weifuchun suppresses the malignancy of gastric cancer cells by targeting KPNA2 through miR-26a-5p-mediated destabilization and the deactivation of the MAPK signaling pathway.
- Galectin-1 Promotes Gastric Carcinoma Progression and Cisplatin Resistance Through the NRP-1/c-JUN/Wee1 Pathway.
- KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner.
- The efficacy and safety of per-nasal "GTS partner" assisted traction technique for gastric endoscopic submucosal dissection: a prospective single-center randomized clinical trial.
- Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
- KCND2: A prognostic biomarker and regulator of immune function in gastric cancer.
- Helicobacter pylori Infection as a Predictor of Treatment Outcomes of Gastric Cancer: A Systematic Review and Meta-Analysis.
- Competing endogenous RNA network characterization of lymph node metastases in Leuran gastric cancer subtypes.
- Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.
- Clinicopathological study of gastric schwannoma and review of related literature.
- Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.
- Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.
- TLR4 rs4986790 polymorphism confers risk to Helicobacter pylori infection in Zhejiang, China and its enlightenment to nursing care.
- Research progress on gut microbiota in patients with gastric cancer, esophageal cancer, and small intestine cancer.
- Circular RNA circCOL6A3_030 is involved in the metastasis of gastric cancer by encoding polypeptide.
- Long non-coding RNA AL139002.1 promotes gastric cancer development by sponging microRNA-490-3p to regulate Hepatitis A Virus Cellular Receptor 1 expression.
- The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.
- Transcription Factor CTCFL Promotes Cell Proliferation, Migration, and Invasion in Gastric Cancer via Activating DPPA2.
- Protein interacting with C-kinase 1 is involved in epithelial-mesenchymal transformation and suppresses progress of gastric cancer.
- Evaluation of the efficiency and safety of combined chemotherapy and molecular-targeted therapy in the treatment of advanced gastric cancer: A protocol for systematic review and meta-analysis.
- RORβ suppresses the stemness of gastric cancer cells by downregulating the activity of the Wnt signaling pathway.
- Immunotherapy of gastric cancer: Past, future perspective and challenges.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 69 篇,占 0.3%。
杭州有 11 家医院列在肺癌下全国有 251 家医院列在肺癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- 分期
- II期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06534762
年龄 18 岁 至 65 岁(登记的条件)
牵头:浙江省人民医院杭州
- 正在招募Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06890598
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙
- 正在招募A Phase 2 Clinical Study of ABSK061 and ABSK043
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06632262
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、济南、石家庄、襄阳、贵阳、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文69
- A KAT7-lncPVT1 positive feedback loop promotes lung cancer carcinogenesis and therapy resistance via H3K14ac/HDGF/PI3K/AKT Axis.
- Analysis of setup error and setup efficiency in SBRT for non-small cell lung cancer via a surface-guided radiation therapy system.
- Utilization of artificial intelligence-based pulmonary nodule target reconstruction software in clinical practice education for standardized training residents.
- LINC01214 Promotes Non-Small Cell Lung Cancer Through the miR-497-3p/HSP90AB1 Axis.
- DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma.
- COL5A2-mediated endoplasmic reticulum stress promotes macrophage M2 polarization in lung adenocarcinoma.
- LZTS3 represses tumorigenesis and radioresistance via CK1δ and β-TrCP-mediated ubiquitination pathway in lung cancer.
- Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer.
- MCOLN1-Mediated Endoplasmic Reticulum Stress Induces Autophagy to Facilitate Lung Cancer Growth, Migration, and Invasion.
- Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial.
- USP28-mediated deubiquitination of FOXK1 activates the Hippo signaling pathway to regulate cell proliferation and radiosensitivity in lung cancer.
- Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.
- Temozolomide and anlotinib as second-line therapy for non-small cell lung cancer patients with brain metastases: a retrospective cohort study.
- Comparative dosimetric evaluation of single-beam dual-arc versus dual-beam single-arc volumetric modulated arc therapy strategies in lung stereotactic body radiotherapy using Monaco.
- A retrospective study of automatic progressive optimization for lung cancer radiotherapy plans on the Halcyon and RayStation systems.
- Poricoic Acid A, an Active Ingredient Extracted From Poria cocos, Inhibits Lung Cancer Cell Growth by Suppressing MEK/ERK Signaling Pathway.
- Dosimetric comparison of Monte Carlo, Acuros XB, and anisotropic analytical algorithm for lung cancer plans on halcyon accelerators.
- Comparative analysis of VMAT plans on Halcyon and infinity for lung cancer radiotherapy.
- Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function.
- Downregulated CDK10 promotes cancer progression and radioresistance in lung cancer through activating the JNK/c-Jun signaling pathway.
- Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.
- COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma.
- A clinical-radiological predictive model for solitary pulmonary nodules and the relationship between radiological features and pathological subtype.
- Re: peritumoural MRI radiomics signature of brain metastases can predict epidermal growth factor receptor mutation status in lung adenocarcinoma.
- NPM3 as an Unfavorable Prognostic Biomarker Involved in Oncogenic Pathways of Lung Adenocarcinoma via MYC Translational Activation.
- microRNA-486-5p Regulates DNA Damage Inhibition and Cisplatin Resistance in Lung Adenocarcinoma by Targeting AURKB.
- Sanguinarine Attenuates Lung Cancer Progression via Oxidative Stress-induced Cell Apoptosis.
- Hypoxia A Typical Target in Human Lung Cancer Therapy.
- Diagnostic Potential of Serum Glycome Analysis in Lung Cancer: A Glycopattern Study.
- Pan-cancer landscape analysis of NOP58 and its oncogenic driving role in lung adenocarcinoma.
- Multi-instance learning based lung nodule system for assessment of CT quality after small-field-of-view reconstruction.
- A combination of radiomic features, clinic characteristics, and serum tumor biomarkers to predict the possibility of the micropapillary/solid component of lung adenocarcinoma.
- Prognostic value of lymph node metrics in lung squamous cell carcinoma: an analysis of the SEER database.
- Promotion of Lung Cancer Metastasis by SIRT2-Mediated Extracellular Protein Deacetylation.
- Diosbulbin C, a novel active ingredient in Dioscorea bulbifera L. extract, inhibits lung cancer cell proliferation by inducing G0/G1 phase cell cycle arrest.
- SIRP-alpha-IL-6 axis induces immunosuppressive macrophages in non-small-cell lung cancer.
- The roles, molecular interactions, and therapeutic value of CDK16 in human cancers.
- Thirdhand Smoke May Promote Lung Adenocarcinoma Development through HN1.
- 68Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging.
- Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma.
- Case report: Interstitial lung disease of XELOEX chemotherapy with cetuximab in advanced colon cancer induced.
- A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers.
- Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer.
- Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study.
- Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats.
- Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.
- Circ_MACF1 targets miR-421 to upregulate FMO2 to suppress paclitaxel resistance and malignant cellular behaviors in lung adenocarcinoma.
- Lung cancer patient with Tropheryma whipplei and Nocardia co-infection.
- Development of Deep Learning-based Automatic Scan Range Setting Model for Lung Cancer Screening Low-dose CT Imaging.
- TECPR1 Induces Apoptosis in Non-Small Cell Lung Carcinoma via ATG5 Upregulation-Induced Autophagy Promotion.
- The CT delta-radiomics based machine learning approach in evaluating multiple primary lung adenocarcinoma.
- Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.
- Knockdown of lncRNA PCAT6 suppresses the growth of non-small cell lung cancer cells by inhibiting macrophages M2 polarization via miR-326/KLF1 axis.
- Classification and Segmentation Algorithm in Benign and Malignant Pulmonary Nodules under Different CT Reconstruction.
- Novel immunotherapeutic drugs for the treatment of lung cancer.
- Two Novel Nomograms Predicting the Risk and Prognosis of Pancreatic Cancer Patients With Lung Metastases: A Population-Based Study.
- Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
- Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines.
- Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis.
- The prognosis of different distant metastases pattern in malignant tumors of the adrenal glands: A population-based retrospective study.
- Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.
- Down-regulation of CLEC3B facilitates epithelial-mesenchymal transition, migration and invasion of lung adenocarcinoma cells.
- Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.
- Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
- Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices.
- MiR-96-5p is an oncogene in lung adenocarcinoma and facilitates tumor progression through ARHGAP6 downregulation.
- A comparative study of auto-contouring softwares in delineation of organs at risk in lung cancer and rectal cancer.
- The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database.
- Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
- Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
- A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
- Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
癌症
胰腺癌
Pancreatic cancer2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 53 篇,占 0.9%。
杭州有 9 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下
这家医院参与的开放试验 8
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
- 分期
- I/II期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07312422
年龄 18 岁 至 75 岁(登记的条件)
牵头:浙江省人民医院杭州
- 正在招募Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- 分期
- II期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06534762
年龄 18 岁 至 65 岁(登记的条件)
牵头:浙江省人民医院杭州
- 正在招募Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06722911
年龄 18 岁 至 75 岁(登记的条件)
牵头:浙江省人民医院杭州
- 正在招募A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- 分期
- II期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07255404
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、昆明、杭州、武汉、沈阳、郑州
- 正在招募A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
- 分期
- II/III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06361888
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、广州、成都、昆明、杭州、武汉、沈阳、济南、海口、深圳、温州、福州、苏州、西安、郑州、重庆、长沙
- 正在招募A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
- 分期
- II期
- 开始
- 2023-05
- 发布
- 登记号
- NCT05859750
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、广州、杭州、武汉、济南
- 正在招募A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
- 分期
- I期
- 开始
- 2023-07
- 发布
- 登记号
- NCT05911217
年龄 18 岁 至 79 岁(登记的条件)
牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、北京、杭州、武汉、西安、郑州、长沙
- 正在招募A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- 分期
- II期
- 开始
- 2023-10
- 发布
- 登记号
- NCT06008288
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、福州、西安、郑州、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文53
- Diagnostic performance of artificial intelligence based on contrast-enhanced computed tomography in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
- 18F-FDG PET Radiomic Analysis to Predict Occult Liver Metastases of Pancreatic Ductal Adenocarcinoma.
- PIM1 protects pancreatic ductal cancer cells from glucose deprivation-induced oxidative stress via OXR1 phosphorylation.
- Extracellular Vesicle-Derived Adenosine as a Diagnostic Metabolic Biomarker for Pancreatic Ductal Adenocarcinoma.
- The acidic microenvironment promotes pancreatic cancer progression via the lncRNA-LOC100507424/E2F1/FOXM1 axis.
- A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment.
- SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma.
- A clinically applicable machine learning model for personalized survival prediction in metastatic pancreatic neuroendocrine tumors.
- Oncogenic Role of PTPN14 in Pancreatic Cancer Through β-Catenin/NF-κB Pathway Activation.
- STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer.
- Small bowel obstruction in patients associated with immune checkpoint inhibitors combined with chemotherapy: Two case reports and a review.
- The Causal Role of Gut Microbiota and Immune Cell Mediation in Gastroenteropancreatic Neuroendocrine Neoplasms: A Mendelian Randomization Study.
- PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer.
- TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through the FAK/AKT/Mtor-gpx4 cascade.
- Predicting textbook outcome after pancreaticoduodenectomy for invasive intraductal papillary mucinous neoplasm: An international validation cohort study.
- β-hydroxybutyrate dehydrogenase promotes pancreatic cancer cell proliferation through regulation of the NAD+/NADH balance and mitochondrial acetylation.
- Antioxidant capacity of the iron-sulfur cluster assembly protein IscU2 is mediated by aspartate metabolism to promote tumor survival.
- Delayed gastric emptying risk stratification in patients with pancreatic ductal adenocarcinoma after pancreatoduodenectomy: An international validation cohort study.
- PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
- Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer.
- WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc.
- Single-cell transcriptomics reveal the prognostic roles of epithelial and T cells and DNA methylation-based prognostic models in pancreatic cancer.
- Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma.
- Interpretable multitemporal liver function indicator model for prediction and risk factor analysis of drug induced liver injury.
- A smart tablet-phone-based high-performance pancreatic cancer cell biosensing system for drug screening.
- Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and pancreatic cancer.
- Causal effect between gut microbiota and pancreatic cancer: a two-sample Mendelian randomization study.
- Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular.
- An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma.
- Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance.
- UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma.
- Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma.
- Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review.
- Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
- CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma.
- CT-based differentiation of solid pseudopapillary neoplasm and nonfunctional neuroendocrine tumor of pancreas.
- Innate immunity in pancreatic cancer: Lineage tracing and function.
- Two Novel Nomograms Predicting the Risk and Prognosis of Pancreatic Cancer Patients With Lung Metastases: A Population-Based Study.
- Algorithm-based care after pancreatic resection.
- Laparoscopic duodenum-preserving pancreatic head resection with real-time indocyanine green guidance of different dosage and timing: enhanced safety with visualized biliary duct and its long-term metabolic morbidity.
- Functions and clinical applications of exosomes in pancreatic cancer.
- PARP inhibitors diminish DNA damage repair for the enhancement of tumor photodynamic therapy.
- ASO Author Reflections: Innovative Techniques for Laparoscopic Duodenum-Preserving Pancreatic Head Resection.
- Laparoscopic radical antegrade modular pancreatosplenectomy: preliminary experience with 10 cases.
- Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis.
- Radiomic nomogram based on MRI to predict grade of branching type intraductal papillary mucinous neoplasms of the pancreas: a multicenter study.
- DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
- Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis.
- A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
- The new role of riluzole in the treatment of pancreatic cancer through the apoptosis and autophagy pathways.
- MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer.
- Comparison of clinical outcomes and quality of life between laparoscopic distal pancreatectomy with or without spleen preservation.
- Adult pancreatoblastoma: a case report.
中文论文(未计入)4
- [Clinical analysis of splenic circulation control technology applied in minimally invasive radical resection of pancreatic neck and body cancer].
- [The outcomes of robotic-assisted enucleation for tumors located in uncinate process of pancreas in 16 cases].
- [Innovation and development of surgical techniques for pancreatic tumors].
- [Clinical effect of minimally invasive duodenum preserving pancreatic head resection for benign and pre-malignant lesions of pancreatic head].
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
- LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
- Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer
- Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo
- Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
- Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer
- Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
- Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic Fistula
- A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
- A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
- A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
- A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
- Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer
癌症
乳腺癌
Breast cancer2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 74 篇,占 0.4%。
杭州有 9 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- 分期
- II期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06534762
年龄 18 岁 至 65 岁(登记的条件)
牵头:浙江省人民医院杭州
- 正在招募A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- 分期
- III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06966700
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 21 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、合肥、哈尔滨、杭州、武汉、济南、西安、郑州、长春、长沙
- 正在招募The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06452706
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、乌鲁木齐、哈尔滨、杭州、武汉、西安
- 正在招募Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- 分期
- III期
- 开始
- 2023-10
- 发布
- 登记号
- NCT05696626
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 57 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、大连、天津、宁波、安阳、广州、徐州、成都、昆明、杭州、梅州、武汉、沈阳、泸州、洛阳、海口、深圳、温州、石家庄、福州、蚌埠、襄阳、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
- 分期
- 不分期
- 开始
- 2023-07
- 发布
- 登记号
- NCT07920094
年龄 18 岁 至 70 岁;仅女性(登记的条件)
牵头:浙江大学医学院附属邵逸夫医院;另有 10 家列出的医院为研究中心台州、宁波、杭州、温州、金华
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文74
- UBE2K promotes breast cancer growth by ubiquitinating and degrading STUB1 to regulate the PKA/CREB1 signaling pathway, forming a feedback loop.
- Uncovering the symptom relationship among sleep quality, anxiety, and depression in Chinese patients with breast cancer: multidimensional data validation using PSQI versus actigraphy.
- Senescence-Inducing Therapy Sequential NIR-II Mild Photothermal/Senolytic Therapy of Triple Negative Breast Cancer.
- Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple-Negative Breast Cancer Models.
- Clinical Experience in the Management of the Polyacrylamide Hydrogel (PAAG) Associated Complications Including Four Breast Cancer Cases: A Retrospective Study of 135 Cases.
- Luminol/PtCo@rGO and Au@CNTs-based electrochemiluminescence cytosensor for ultrasensitive detection of breast cancer CTCs.
- Development and validation of an 18F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study.
- Trends in the global, national, and regional burden of breast cancer among adolescents and young adults from 1990 to 2021: Analyses of the 2021 global burden of disease study.
- Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.
- Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study.
- Interpretable Machine Learning for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer Using the Baseline Clinical and Pathological Characteristics.
- SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma.
- Breast Cancer in Working-Age Men: A Population-Based Investigation of Global, Regional, and National Disease Burdens Between 1990 and 2021.
- Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling.
- Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery.
- Integrative single-cell and bulk RNA sequencing of lactate metabolism identifies PDP-1 as a prognostic biomarker in breast cancer.
- MR imaging of breast cancer: Interpretable radiomics analysis to assess treatment response and survival prognosis after neoadjuvant therapy.
- Xihuang pill suppresses breast cancer malignancy by inhibiting TGF-β signaling and acquires chemotherapy benefits.
- Acetylation suppresses breast cancer progression by sustaining CLYBL stability.
- Fibroblast Activation Protein (FAP)+ cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin α5β1 axis in breast cancer.
- Enhancing breast magnetic resonance imaging segmentation with a federated semi-supervised approach.
- Implication of an exosome-based gene signature for estimating clinical outcomes of triple-negative breast cancer and assisting in individualized therapy.
- Machine learning analysis of coagulation-related genes for breast cancer diagnosis and prognosis prediction.
- The impact of axillary lymph node dissection on the prognosis of breast cancer patients undergoing up-front mastectomy with Sentinel lymph node micrometastases.
- Tumor-colonizing Pseudoalteromonas elyakovii metabolically reprograms the tumor microenvironment and promotes breast ductal carcinoma.
- 3D-Printed Breast Prosthesis that Smartly Senses and Targets Breast Cancer Relapse.
- Prediction of neoadjuvant chemotherapy pathological complete response for breast cancer based on radiomics nomogram of intratumoral and derived tissue.
- Research progress in tumor angiogenesis and drug resistance in breast cancer.
- Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.
- Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients.
- Whole transcriptome sequencing indicated the Anti-tumor immunity of NLRP3 in breast cancer.
- CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer.
- Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer patients: use of MRI radiomics data from three regions with multiple machine learning algorithms.
- The crosstalk between benign thyroid disease and breast cancer: A single center study.
- Methylation modification of non-histone proteins in breast cancer: An emerging targeted therapeutic strategy.
- The role of adjuvant endocrine treatment in ER+, PR-, HER2- early breast cancer: a retrospective study of real-world data.
- Platelet Membrane Coated Cu9S8-SNAP for Targeting NIR-II Mild Photothermal Enhanced Chemodynamic/Gas Therapy of Triple-Negative Breast Cancer.
- Estimated cardiorespiratory fitness in relation to overall, breast and prostate cancer incidence: the Norwegian HUNT study.
- Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer.
- Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study.
- Gut microbiome causal impacts on the prognosis of breast cancer: a Mendelian randomization study.
- Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway.
- Synthesis of poly (L-cysteine)/g-C3N4 modified glassy carbon electrodes for electrochemical detection of methotrexate as a medicine for treatment of breast cancer in pharmaceutical fluid samples.
- Hsa-miR-105-5p acts as an oncogene in triple-negative breast cancer.
- Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.
- Establishing a Predictive Model to Predict Survival of de Novo Metastatic HER2-Low Breast Cancer: A National Cancer Database Analysis.
- Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer.
- Integrated analysis of FKBP1A/SLC3A2 axis in everolimus inducing ferroptosis of breast cancer and anti-proliferation of T lymphocyte.
- Correlation between the setting of gating window width and setup accuracy in left breast cancer radiotherapy based on deep inspiration breath hold.
- Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses.
- NIR diagnostic imaging of triple-negative breast cancer and its lymph node metastasis for high-efficiency hypoxia-activated multimodal therapy.
- OTUD1 chemosensitizes triple-negative breast cancer to doxorubicin by modulating P16 expression.
- Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.
- FKBP5 associated CD8 T cell infiltration is a novel prognostic biomarker in luminal B breast cancer.
- Breast cancer organoids and their applications for precision cancer immunotherapy.
- Engineered Red Blood Cell Membrane-Coating Salidroside/Indocyanine Green Nanovesicles for High-Efficiency Hypoxic Targeting Phototherapy of Triple-Negative Breast Cancer.
- Two-dimensional speckle tracking echocardiography help identify breast cancer therapeutics-related cardiac dysfunction.
- Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
- Thyrotropin suppression therapy using levothyroxine does not negatively affect breast cancer prognosis.
- Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery.
- Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
- miR-10b-5p-mediated upregulation of PIEZO1 predicts poor prognosis and links to purine metabolism in breast cancer.
- Autophagy-related prognostic signature for survival prediction of triple negative breast cancer.
- Metastasis patterns and prognosis of octogenarians with metastatic breast cancer: A large-cohort retrospective study.
- Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study.
- Breast metastasis of signet ring cell carcinoma from the colon: a case report.
- Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective stu
- Integrative genomic analysis of N6-methyladenosine-single nucleotide polymorphisms (m6A-SNPs) associated with breast cancer.
- Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer.
- Naringenin Regulates FKBP4/NR3C1/NRF2 Axis in Autophagy and Proliferation of Breast Cancer and Differentiation and Maturation of Dendritic Cell.
- Role of immune regulatory cells in breast cancer: Foe or friend?
- Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway.
- Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
- Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
- A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
- A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
- Breast Mesh Used in Two-staged Breast Reconstruction
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
- Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
- Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
- Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
癌症
胶质瘤
Glioma2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 24 篇,占 0.3%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 9 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
- 分期
- 未注明
- 开始
- 2025-06
- 发布
- 登记号
- NCT06939400
年龄 18 岁 至 未注明(登记的条件)
牵头:浙江省人民医院杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文24
- Metalloporphyrin organic framework oxygen-generators enable tumour-targeted photodynamic therapy and metabolic reprogramming for enhanced glioblastoma treatment.
- Biomimetic platinum-based nanoplatform for photoacoustic imaging-guided multimodal glioblastoma therapy.
- Integration of Single-Cell and Bulk RNA-seq Data to Identify the Cancer-Associated Fibroblast Subtypes and Risk Model in Glioma.
- Novel Insights Into Small Open Reading Frame-Encoded Micropeptides in Glioblastoma.
- Mechanistic Insights into the Anti-Glioma Effects of Exosome-Like Nanoparticles Derived from Garcinia Mangostana L.: A Metabolomics, Network Pharmacology, and Experimental Study.
- ApoE-Corona oncolytic adenovirus nanoparticles enable blood-brain barrier penetration for glioblastoma immunotherapy.
- Exosomal circ_0001583 Drives Glioblastoma Cell Advancement Through the miR-647/CKAP2L Pathway.
- Three Decades of Photodynamic Therapy for Glioblastoma: A Comprehensive Scientometric Analysis.
- Glioma stem cells: drivers of tumor progression and recurrence.
- β-Mangostin targets and suppresses glioma via STING activation and tumor-associated microglia polarization.
- Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
- Inhibition of circular JUN prevents the proliferation and invasion of glioblastoma via miR-3064-IGFBP5 axis.
- The Implication of Photodynamic Therapy Applied to the Level of Tumor Resection on Postoperative Cerebral Edema and Intracranial Pressure Changes in Gliomas.
- Turning attention to tumor-host interface and focus on the peritumoral heterogeneity of glioblastoma.
- EGFR-Induced and c-Src-Mediated CD47 Phosphorylation Inhibits TRIM21-Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion.
- The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
- NIR-II absorptive dithienopyrrole-thiadiazolobenzotriazole conjugated polymer for photoacoustic imaging-guided glioblastoma multiforme photothermal therapy.
- Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.
- IGFBPs were associated with stemness, inflammation, extracellular matrix remodeling and poor prognosis of low-grade glioma.
- Inhibition of hypoxia-inducible factor 1 by acriflavine renders glioblastoma sensitive for photodynamic therapy.
- TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells.
- Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
- Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma.
- The Nomogram of MRI-based Radiomics with Complementary Visual Features by Machine Learning Improves Stratification of Glioblastoma Patients: A Multicenter Study.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 20 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文4
- Brusatol induced ferroptosis in osteosarcoma cells by modulating the Keap1/Nrf2/SLC7A11 signaling pathway.
- Recent advances in nanoagents delivery system-based phototherapy for osteosarcoma treatment.
- Osteoclasts differential-related prognostic biomarker for osteosarcoma based on single cell, bulk cell and gene expression datasets.
- LncRNA CASC9 promotes cell proliferation and invasion in osteosarcoma through targeting miR-874-3p/SOX12 axis.
早期论文(2016–2020 年)5
- miR-33a Mediates the Anti-Tumor Effect of Lovastatin in Osteosarcoma by Targeting CYR61.
- Heterogeneous expression and biological function of SOX18 in osteosaroma.
- Misdiagnosed as osteosarcoma: Brown tumour in a haemodialysis patient.
- Potential mechanisms underlying CDK5 related Osteosarcoma progression.
- [Clinicopathologic and molecular characteristics of malignant gastrointestinal neuroectodermal tumors].
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 8 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 6 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- 分期
- I期
- 开始
- 2025-05
- 发布
- 登记号
- NCT06926283
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、杭州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 9 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文10
- Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid.
- Performance and comparison of FLCCheck: a novel serum free light chain assay for the Auxiliary Diagnosis of Multiple Myeloma.
- Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.
- Regarding the prognostic role of vitamin D deficiency in a Japanese multiple myeloma study.
- Immunoglobulin Replacement Therapy for Hypogammaglobulinemia in Multiple Myeloma Should Not Be Ignored.
- Defects and countermeasures in laboratory diagnosis of rare IgE multiple myeloma.
- Role of Tfh17 cells in patients with multiple myeloma.
- A patient with hypercalcemia and hyperparathyroidism due to adenoma mimicking multiple myeloma.
- Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China.
- Bone marrow stromal cells derived exosomal miR-10a and miR-16 may be involved in progression of patients with multiple myeloma by regulating EPHA8 or IGF1R/CCND1.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
血液疾病
淋巴瘤
Lymphoma2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.4%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 8 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- 分期
- II期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06534762
年龄 18 岁 至 65 岁(登记的条件)
牵头:浙江省人民医院杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文15
- Tumor Pro-Senescence Strategy to Enhance Mild Photothermal Therapy of Diffuse Large B-Cell Lymphoma.
- Bi-targeting of thioredoxin 1 and telomerase by thiotert promotes cell death of myelodysplastic syndromes and lymphoma.
- Causal association between endocrine diseases and lymphoid malignancies explored through two-sample Mendelian randomization analysis.
- C-MYC-activated lncRNA SNHG20 accelerates the proliferation of diffuse large B cell lymphoma via USP14-mediated deubiquitination of β-catenin.
- Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL.
- TNFAIP3 Overexpression Inhibits Diffuse Large B-Cell Lymphoma Progression by Promoting Autophagy through TLR4/MyD88/NF-κB Signaling Pathway.
- Importance of Rare Gene Alterations in the Prognosis of B-Cell Acute Lymphoblastic Leukemia.
- A patient with the highly suspected B cell lymphoma accompanied by the erythrocytes cold agglutination: Case report.
- Use of Ultrasound to Observe Mycosis Fungoides: A Case Report and Review of Literature.
- Primary pulmonary mucosa-associated lymphoid tissue lymphoma with radiological presentation of middle lobe syndrome diagnosed by bronchoscopy: a case report.
- Caution the difference between the atypical lymphocyte with circulating Hodgkin lymphoma cells.
- Pericardial involvement in a common B-cell acute lymphoblastic leukemia patient.
- New-onset Systemic Lupus Erythematosus in a Woman with Previous Lymphoma during Late Pregnancy: a case report and literature review.
- Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.
- Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 6 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
冠心病
Coronary heart disease2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.2%。
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 11 家医院列在冠心病下全国有 231 家医院列在冠心病下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
- 分期
- II期
- 开始
- 2026-07
- 发布
- 登记号
- NCT07521007
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、合肥、哈尔滨、天津、广州、成都、杭州、武汉、福州、苏州、西安、长春、长沙
- 正在招募Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
- 分期
- IV期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07110415
年龄 40 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、兰州、北京、南京、南宁、哈尔滨、大庆、大连、天津、宁波、广州、张家口、成都、杭州、汕头、沈阳、济南、深圳、湖州、烟台、珠海、石家庄、西安、贵阳、重庆、银川、长春、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文12
- The relationship between Non-HDL/HDL ratio and in-stent restenosis in patients with coronary artery atherosclerosis after percutaneous coronary intervention.
- Underlining the Molecular Mechanism of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in Lipid Metabolism by Combining Multiple Sets of Data Sets.
- Association of 24-Hour blood pressure average real variability with poor prognosis in critically ill patients with coronary artery disease.
- Serum Angptl2 and CyPA Levels in Acute Myocardial Infarction and In-Stent Restenosis After Percutaneous Coronary Intervention: A Single-Center Retrospective Case-Control Study.
- Coronary artery calcium scoring assessment in ultra-low-dose chest computed tomography.
- Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease.
- Spontaneous multivessel coronary artery spasm: a case report.
- Lower Baseline LDL Cholesterol Affects All-cause Mortality in Patients with First Percutaneous Coronary Intervention.
- Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
- Coronary computed tomography angiography imaging features combined with computed tomography-fractional flow reserve, pericoronary fat attenuation index, and radiomics for the prediction of myocardial ischemia.
- Coronary artery calcification in patients with advanced chronic kidney disease.
- Predicting Chronic Myocardial Ischemia Using CCTA-Based Radiomics Machine Learning Nomogram.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
其他疾病
先天性心脏病
Congenital heart disease2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 9 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下
截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。
这些数字背后的记录
牵头的论文5
- Clinical observation of 4 cases of cerebral infarction caused by left ventricular noncompaction.
- The molecular mechanism of MiR-26a-5p regulates autophagy and activates NLRP3 inflammasome to mediate cardiomyocyte hypertrophy.
- To the Editor - Risk of atrial arrhythmias in arrhythmogenic right ventricular cardiomyopathy patients undergoing ventricular tachycardia ablation.
- Commentary on the mitral regurgitation outcomes after transcatheter atrial septal defect closure.
- The rare cause of ST segment elevation in left precordial leads - Diagnostic clues from subtle waveforms.
其他疾病
脊柱侧弯
Scoliosis2021–2025 年中国大陆作者发表的 925 篇脊柱侧弯 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
杭州有 6 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Protocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS
- 分期
- 不分期
- 开始
- 2025-03
- 发布
- 登记号
- NCT06314594
年龄 12 岁 至 16 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- Correlations of spinopelvic parameters with quality of life of patients with adult degenerative scoliosis after posterior correction.
- Letter to the Editor Regarding "An Optimized Enhanced Recovery After Surgery (ERAS) Pathway Improved Patient Care in Adolescent Idiopathic Scoliosis Surgery: A Retrospective Cohort Study".
- Bibliometric Analysis of the Scientific Literature on Adolescent Idiopathic Scoliosis.
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 10 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在法布雷病下全国有 80 家医院列在法布雷病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 10 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文4
- Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching.
- A patient report scale research to access the symptom burden in patients with IgA nephropathy.
- Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy.
- Mesangial Cell-Derived Exosomal miR-4455 Induces Podocyte Injury in IgA Nephropathy by Targeting ULK2.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- MYTP01 for Immune-Mediated Diseases
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 7 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
牵头的论文4
- Rosacea and autoimmune liver diseases: a two-sample Mendelian randomization study.
- Causal association between autoimmune liver disease and Sjögren's syndrome: A Mendelian randomization study.
- Identifying the genetic association between systemic lupus erythematosus and the risk of autoimmune liver diseases.
- Letter to the Editor: Is Male Sex Associated With Increased Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis?
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
杭州有 6 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
其他相关研究
联系这家医院
出示给工作人员或司机的院名卡
浙江省人民医院
Zhejiang Provincial People's Hospital
杭州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Zhejiang Provincial People's Hospital (Affiliated People's Hospital); Zhejiang Provincial People's Hospital (Affiliated People's Hospital; Zhejiang Provincial People's Hospital(Affiliated People's Hospital); Zhejiang Provincial People's Hospital Chun'an Branch; Zhejiang Provincial People's hospital; Zhejiang Provincial People's Hospital Bijie Hospital; Affiliated Zhejiang Provincial People's Hospital; Zhejiang Provincial People' s Hospital